The Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting

On July 30, the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated with an increased risk of myocardial ischemic events. Dr. Clifford Rosen reports.